What is the appropriate immediate‑release Cymbalta (duloxetine) dose for a patient currently on 30 mg extended‑release?

Cymbalta Immediate-Release Formulation Does Not Exist

There is no immediate-release formulation of Cymbalta (duloxetine) available—only delayed-release capsules exist, and these must be swallowed whole without opening, crushing, or chewing. 1

Critical Formulation Information

The FDA-approved Cymbalta formulation is exclusively delayed-release (enteric-coated) capsules. The drug label explicitly states:

• Cymbalta must be swallowed whole
• Cannot be chewed or crushed
• Capsule cannot be opened and contents sprinkled on food or mixed with liquids
• All of these actions would compromise the enteric coating 1

If Your Patient is Taking 30 mg Extended-Release

Continue the same 30 mg delayed-release capsule once daily. There is no conversion needed because:

1. All Cymbalta formulations are delayed-release by design
2. The 30 mg dose is already the appropriate starting dose for most indications 1
3. Duloxetine has a sufficiently long elimination half-life (12 hours) to permit single daily dosing 2, 3

Standard Dosing Algorithm

Based on FDA labeling and clinical guidelines 1:

For most indications:

• Start: 30 mg once daily for 1 week (to reduce nausea)
• Target: 60 mg once daily
• Maximum: 120 mg/day (though no evidence of additional benefit beyond 60 mg for most conditions)

Specific conditions:

• Major Depression: 40-60 mg/day (can give as 20 mg twice daily or 30 mg twice daily initially) 1
• Generalized Anxiety Disorder: Start 30 mg daily × 1 week, then 60 mg daily 4, 1
• Diabetic Neuropathic Pain: 60 mg once daily (no benefit from higher doses) 5, 6, 7
• Fibromyalgia: 30 mg daily × 1 week, then 60 mg daily 1

Common Pitfall to Avoid

Do not attempt to create an "immediate-release" version by opening capsules or crushing tablets—this does not exist and would:

• Destroy the enteric coating designed to prevent premature drug release
• Potentially cause increased gastrointestinal side effects
• Result in unpredictable pharmacokinetics

Clinical Considerations

If tolerability is a concern at 30 mg:

• The 30 mg dose can be maintained as some patients respond to this lower dose 1
• Slower titration is appropriate for elderly patients 4
• Consider dose reduction in hepatic or severe renal impairment 1

The most common adverse effect is nausea, which is reduced by starting at 30 mg for one week before increasing 5. Blood pressure monitoring is recommended as duloxetine can cause mild increases 2.